OMED OncoMed Pharmaceuticals, Inc.

3.91
+0  (4%)
Previous Close 3.77
Open 3.75
Price To book 0.00
Market Cap 146.23M
Shares 37,398,000
Volume 575,788
Short Ratio 10.50
Av. Daily Volume 364,329

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released April 10, 2017 - primary endpoint not met.
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Phase 2 data are 1H 2017. Announced November 1, 2016 that it has discontinued further enrollment.
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2 data released April 17, 2017 - primary endpoint not met.
Tarextumab - PINNACLE trial
Small cell lung cancer
Company announced late January 2016 that they plan to unblind the trial following notice from the DSMB that suggests a low likelihood of a statistically significant benefit in overall survival. Subsequently, in February 2016 an announcement was made to discontine the trial
Tarextumab ALPINE
Pancreatic Cancer

Latest News

  1. Bay Area biotech slashes half of staff after drug partnerships falter
  2. OncoMed to lay off half of its staff
  3. OncoMed Announces Workforce Reduction
  4. Here's Why OncoMed Pharmaceuticals (OMED) Stock Fell Today
  5. OncoMed is having a no good, very bad week
  6. OncoMed's lung cancer drug fails mid-stage study, shares tumble
  7. Biotech Movers: OncoMed, Incyte, Omeros
  8. OncoMed stock drops 25% after lung cancer drug misses in mid-stage clinical trial
  9. OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
  10. OncoMed Cancer Candidate Fails Trial, Bayer Opts Out of Deal
  11. Do Any Signs Of Life Remain In OnceMed's Demcizumab Development?
  12. Peninsula biotech tumbles as cancer trial fails, Bayer nixes drug option
  13. Why OncoMed Pharmaceuticals, AK Steel, and Intrawest Resorts Holdings Slumped Today
  14. Biotechs Split: Axovant Rides CEO Swap, But Celgene Partner Dives
  15. Coty, DryShips Sink into Monday’s 52-Week Low Club
  16. OncoMed Plunges On 'Double Setback'
  17. Why Oncomed Pharmaceuticals Inc. Got Slaughtered Today
  18. Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk
  19. OncoMed Cancer Drug Fails, Loses Bayer Partnership
  20. OncoMed Hits All-Time Low After Failed Trial and Licensing Fallout